Q-omics provides the consensus-scored BMERB1 profile across patient tissues and cancer cell-line models. BMERB1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, BMERB1 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, BMERB1 RNA expression shows 20,283 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UVM, KIRC, and BRCA as cancer lineages where BMERB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BMERB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BMERB1 survival associations across molecular data types. BMERB1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BMERB1 RNA expression–survival associations across cancer types. High BMERB1 expression shows unfavorable associations in UVM, LUSC and LAML, but favorable associations in LIHC, KIRC and SKCM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for BMERB1 RNA expression.
This table summarizes BMERB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for BMERB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BMERB1 shows lower tumor expression in KIRC, KICH, BLCA, COAD and LUSC and higher tumor expression in THCA. The KIRC box plot shows higher BMERB1 RNA expression in normal versus tumor tissue (log2 FC = −1.168, t-test p < 0.001).
This table shows molecular features associated with BMERB1 in patient tissues and cancer cell lines. In patient samples, BMERB1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, BMERB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SKIN and CNS.
